Literature DB >> 8540595

Hypothalamic-pituitary-adrenal axis activity in panic disorder: prediction of long-term outcome by pretreatment cortisol levels.

J L Abelson1, G C Curtis.   

Abstract

OBJECTIVE: The authors sought to determine whether hypothalamic-pituitary-adrenal (HPA) axis activity in patients before their treatment for panic disorder can predict follow-up functional status. Although baseline HPA axis disturbances in patients with panic disorder appear to attenuate with treatment, there is evidence that they may be linked to poorer long-term outcomes.
METHOD: Follow-up clinical data were obtained for 18 of 20 patients with panic disorder who participated in a detailed study of HPA axis activity in panic, both before and during their treatment with alprazolam. HPA axis assessment included monitoring of adrenocorticotropin and cortisol over a full circadian cycle. The relationships between disability and clinical status at 2-year follow-up and HPA axis overactivity at entry were examined.
RESULTS: Mean 24-hour cortisol levels before treatment provided a strong, positive predictor of disability scores at follow-up. Those patients who achieved the treatment goal of medication-free remissions had less evidence of HPA axis overactivity at entry than those who were not in remission.
CONCLUSIONS: HPA axis activity before treatment did predict outcome 2 years later. This relationship appears robust and reproducible. Further work is needed to define the neuroendocrine mechanisms underlying the HPA axis markers that are linked to long-term functioning and to determine the biological, psychological, and social processes that link HPA axis disturbance to poorer outcomes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8540595     DOI: 10.1176/ajp.153.1.69

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  6 in total

Review 1.  Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets.

Authors:  Richard L Hauger; Victoria Risbrough; Olaf Brauns; Frank M Dautzenberg
Journal:  CNS Neurol Disord Drug Targets       Date:  2006-08       Impact factor: 4.388

2.  Release of vasopressin within the rat paraventricular nucleus in response to emotional stress: a novel mechanism of regulating adrenocorticotropic hormone secretion?

Authors:  C T Wotjak; M Kubota; G Liebsch; A Montkowski; F Holsboer; I Neumann; R Landgraf
Journal:  J Neurosci       Date:  1996-12-01       Impact factor: 6.167

Review 3.  The underlying neurobiology of key functional domains in young people with mood and anxiety disorders: a systematic review.

Authors:  Frank Iorfino; Ian B Hickie; Rico S C Lee; Jim Lagopoulos; Daniel F Hermens
Journal:  BMC Psychiatry       Date:  2016-05-23       Impact factor: 3.630

4.  Presurgical Psychological and Neuroendocrine Predictors of Psychiatric Morbidity After Major Vascular Surgery: A Prospective Longitudinal Study.

Authors:  Anthony P King; James L Abelson; Bardia Gholami; Gilbert R Upchurch; Peter Henke; Linda Graham; Israel Liberzon
Journal:  Psychosom Med       Date:  2015 Nov-Dec       Impact factor: 4.312

5.  Development of an integrated cognitive behavioral therapy for anxiety and opioid use disorder: Study protocol and methods.

Authors:  R Kathryn McHugh; Victoria R Votaw; David H Barlow; Garrett M Fitzmaurice; Shelly F Greenfield; Roger D Weiss
Journal:  Contemp Clin Trials       Date:  2017-07-08       Impact factor: 2.226

Review 6.  Neuroendocrine host factors and inflammatory disease susceptibility.

Authors:  S Ligier; E M Sternberg
Journal:  Environ Health Perspect       Date:  1999-10       Impact factor: 9.031

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.